Carl June’s Cancer Startup Raises $100 Million From Gilead, Sean Parker – Forbes
Forbes |
Carl June’s Cancer Startup Raises $100 Million From Gilead, Sean Parker
Forbes Both attempt to use genetically modified T–cells, which have proven effective in late-stage blood cancers, against more common solid tumors, which are more difficult for the immune system to penetrate. One treatment is what is known as a chimeric … Tmunity Reels in $100M for “Next Generation” Cancer ImmunotherapyXconomy |
|
BioLineRx’s immunotherapy candidate AGI-134 shows positive effect in preclinical melanoma studies; shares ahead 8 …
Seeking Alpha BioLineRx (NASDAQ:BLRX) is up 8% premarket on light volume in response to its announcement of positive results from preclinical studies assessing immunotherapy candidate AGI-134. The data will be presented at the ASCO-SITC Clinical Immuno-Oncology … BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical …PR Newswire (press release) |
Labiotech.eu (blog) |
uniQure Gets Orphan Medicinal Product Designation for Huntington’s Gene Therapy
Labiotech.eu (blog) The EMA has given uniQure’s gene therapy candidate for Huntington’s disease Orphan Medicinal Product Designation, which the company hopes to move into the clinic this year. uniQure is known for Glybera, Europe’s first gene therapy. The company’s … |